Monoclonal antibody therapy in multiple sclerosis

Current Views on the Roles of Th1 and Th17 Cells in Experimental Autoimmune Encephalomyelitis

(2010) Mohamed El-behi et al.   Journal of Neuroimmune Pharmacology

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

(2010) Samantha Jilek et al.   LANCET NEUROLOGY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Monoclonal antibodies and progressive multifocal leukoencephalopathy

(2010) Joseph R. Berger et al.   mAbs

Primary central nervous system lymphoma in a patient treated with natalizumab

(2009) Andreas Schweikert et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

(2009) Michael Elliott et al.   Annals of the New York Academy of Sciences

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies

(2009) Eugene O. Major   Annual Review of Medicine

Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro

(2009) M. Brickelmaier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis

(2009) Unsong Oh et al.   ARCHIVES OF NEUROLOGY

Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis

(2009) Bibiana Bielekova et al.   ARCHIVES OF NEUROLOGY

Emerging Therapies for Relapsing Multiple Sclerosis

(2009) Jeffrey A. Cohen   ARCHIVES OF NEUROLOGY

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

Monoclonal antibody treatments for multiple sclerosis

(2009) John W. Rose et al.   Current Treatment Options in Neurology

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

(2009) Jorge Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Roles of B lymphocytes in multiple sclerosis: diversifying beyond the antibody response

(2009) Paulo Fontoura   Immunotherapy

Detection of JC Virus DNA and Proteins in the Bone Marrow of HIV‐Positive and HIV‐Negative Patients: Implications for Viral Latency and Neurotropic Transformation

(2009) Chen S. Tan et al.   JOURNAL OF INFECTIOUS DISEASES

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

(2009) Kenneth R Carson et al.   LANCET ONCOLOGY

Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?

(2009) Roberto Bergamaschi et al.   Multiple Sclerosis Journal

Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes

(2009) H. Wiendl et al.   NEUROLOGY

The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

(2009) E. C. Klawiter et al.   NEUROLOGY

Monoclonal antibodies in MS: Mechanisms of action

(2009) B. Bielekova et al.   NEUROLOGY

Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab

(2009) Yiping Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Neuromyelitis Optica With Rituximab

(2008)   ARCHIVES OF NEUROLOGY

Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab

(2008) Maria del Pilar Martin   ARCHIVES OF NEUROLOGY

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: Are patients with systemic lupus erythematosus at particular risk?

(2008) Eamonn S. Molloy et al.   AUTOIMMUNITY REVIEWS

Disease-Modifying Agents for Multiple Sclerosis

(2008) Til Menge et al.   DRUGS

LINGO-1 antagonists as therapy for multiple sclerosis:in vitroandin vivoevidence

(2008) Richard A Rudick et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Treating multiple sclerosis with monoclonal antibodies

(2008) Mathias Buttmann et al.   Expert Review of Neurotherapeutics

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients

(2008) Raija L.P. Lindberg et al.   JOURNAL OF NEUROIMMUNOLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Getting specific: monoclonal antibodies in multiple sclerosis

(2008) Andreas Lutterotti et al.   LANCET NEUROLOGY

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

B cells and multiple sclerosis

(2008) Diego Franciotta et al.   LANCET NEUROLOGY

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

(2008) HF Petereit et al.   Multiple Sclerosis Journal

Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary

(2008) Rocio S. Lopez-Diego et al.   NATURE REVIEWS DRUG DISCOVERY

The Use of MR Imaging as an Outcome Measure in Multiple Sclerosis Clinical Trials

(2008) Robert A. Bermel et al.   NEUROIMAGING CLINICS OF NORTH AMERICA

Progressive Multifocal Leukoencephalopathy

(2008) Thomas Weber   NEUROLOGIC CLINICS

Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2008) D. S. Goodin et al.   NEUROLOGY

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

(2008) M. Krumbholz et al.   NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neuromyelitis Optica: A New Perspective

(2008) Sean Pittock   SEMINARS IN NEUROLOGY

Identification and development of new therapeutics for multiple sclerosis

(2008) Ralf A. Linker et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

B cells as therapeutic targets in autoimmune neurological disorders

(2008) Marinos C Dalakas   Nature clinical practice. Neurology

Update on PML: Lessons from the HIV uninfected and new insights in pathogenesis and treatment

(2008) Elizabeth A. Hartman et al.   Current HIV/AIDS Reports